Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals has received more than $500 million in upfront and milestone payments from its portfolio of pharma, technology and data partnerships as of the second quarter of 2026, with cash, cash equivalents and restricted cash totaling $556.8 million at the end of June and a runway the company expects to extend into early 2028 without additional financing. Through its Bayer collaboration, Recursion is advancing precision oncology programs and is eligible for up to $1.5 billion in potential development and commercial milestones plus tiered royalties, while its partnerships with Roche and its wholly-owned subsidiary Genentech cover neuroscience and gastrointestinal oncology and could support up to 40 programs, each potentially generating more than $300 million in milestones plus tiered royalties. In the second quarter of 2026, Genentech advanced the first neuroscience target from the collaboration into early discovery, and partnerships with Sanofi and Merck KGaA offer up to $5.2 billion and $674 million respectively in potential milestone payments in addition to royalties. Recursion has also strengthened its AI infrastructure, with its NVIDIA partnership supporting the development of BioHive-2 and its 2024 combination with Exscientia enhancing computational chemistry and automated drug-design capabilities, and by August 2026 it had built and curated more than 50 petabytes of multimodal data. Technology and data partnerships with Google Cloud, Helix, Tempus and HealthVerity further broaden its platform, while competitors Relay Therapeutics and Schrödinger continue to build their own pipelines, and RXRX shares have lost 9.6% year to date against the industry's 8.5% growth, with 2026 loss estimates narrowing from $1.01 to 94 cents per share over the past 60 days.

Goldman Sachs initiated coverage of Tempus AI with a Neutral rating and a $75 price target on September 21, flagging renewal risk in the company's data business even as diagnostics growth stays visible. The call landed the same day Tempus announced an extension of its partnership with Recursion Pharmaceuticals through 2029, replacing potentially discretionary fees with $42 million of committed payments. Tempus generated $382.5 million of second-quarter revenue, up 22% year-over-year, with Diagnostics revenue up 20% to $289.3 million, oncology volumes up 31%, and MRD testing at 9,000 tests, up 38% from the prior quarter. The Data and Applications segment grew faster, with revenue up 28% in the quarter and Insights revenue up 36%, alongside roughly $200 million in new Data and Applications licenses signed during the quarter. Management estimates FDA approval of tumor-only xT CDx could add about $85 million of annual revenue beginning in 2027, while the company also received FDA clearance for a third cardiovascular AI product and was selected for an ARPA-H program worth up to $9.5 million. Short interest stood at 29.46 million shares, or 29.17% of the float, down from 33.23 million a month earlier, while ARK Investment Management raised its stake 5% to 10.02 million shares and Citadel expanded its position 318% to 2.51 million shares.

Cathie Wood's Ark Genomic Revolution ETF holds more than $50 million worth of Recursion Pharmaceuticals stock, making the $1.8 billion AI-driven drug discovery company a notable position beyond the fund's top 10 holdings. Recursion uses robotics and computer vision to run millions of cell experiments weekly and has seven drugs in clinical stages, with candidate REC-4881 showing positive proof-of-concept data and further results expected in the first half of 2027. The company has partnerships with Bayer, Roche Holding, and Nvidia, and forecasts sufficient cash to operate through early 2028 without additional financing. Recursion generates limited revenue from collaborations and has no marketed drugs, making it a high-risk, high-reward speculative investment in a competitive AI drug-discovery field.

Recursion Pharmaceuticals saw its stock rise roughly 19% over the past month after Cathie Wood's ARK Investment bought 260,000 shares on June 24. The clinical-stage biotechnology company, which builds an AI-native drug discovery platform, highlighted progress in its fiscal first-quarter 2026 earnings, including early safety data for cancer drug REC-1245 and strong Phase 2 results for REC-4881 that prompted FDA talks toward approval. Revenue fell to $6.5 million from $14.7 million a year ago due to a completed Roche partnership phase, but net loss narrowed to $117.5 million from $202.5 million. Analysts expect more than 76% upside from current levels.

Zacks Investment Research identifies Autolus Therapeutics, NextCure, and Recursion Pharmaceuticals as three cancer-focused stocks worth evaluating amid accelerating oncology innovation. Autolus, a commercial-stage company, markets the CAR-T therapy Aucatzyl for relapsed or refractory B-cell acute lymphoblastic leukemia and has guided 2026 net product revenues of $120-$135 million. NextCure is advancing two lead antibody-drug conjugate programs, including SIM0505, which showed a 55% objective response rate in heavily pretreated gynecologic cancers in early data. Recursion Pharmaceuticals, a clinical-stage TechBio company, is developing a pipeline of precision oncology candidates, with its most advanced asset REC-1245 showing encouraging early safety and pharmacokinetic data. All three stocks carry a Zacks Rank #2 (Buy).

Artificial intelligence is reshaping drug discovery by cutting development timelines from years to weeks, targeting a pipeline where 90% of candidates fail to reach approval. Eli Lilly's tirzepatide franchise generated $36.5 billion in 2025 revenue, a 215% increase, while Novo Nordisk's GLP-1 portfolio reached $34.6 billion. Schrodinger's physics-based simulation software serves 18 of the world's 20 largest pharma companies and posted 12% revenue growth in Q1 2026. AI is particularly suited to peptide-based medicines, enabling faster discovery and more precise molecular design. Investors can gain exposure through established leaders like Eli Lilly and Novo Nordisk, or through AI-focused platforms such as Schrodinger and Recursion Pharmaceuticals.

Recursion Pharmaceuticals and Summit Therapeutics present contrasting investment cases in the biotech sector, with Recursion leveraging an AI-driven platform across multiple partnerships while Summit bets heavily on a single oncology drug candidate. Recursion reported fiscal 2025 revenue of nearly $74.7 million, a 26.9% year-over-year increase, but posted a net loss of close to $644.8 million and negative free cash flow of nearly $378.3 million. Summit generated no revenue in fiscal 2025 and recorded a net loss of approximately $1.1 billion, driven by late-stage trials for its lead candidate ivonescimab, with negative free cash flow of close to $240.2 million. Recursion trades at a price-to-sales ratio of 19.3, while Summit has no such ratio due to a lack of product sales. The analysis favors Recursion for its diversified client base and smaller loss, citing Summit's high concentration risk on a single drug and partnership.

Recursion Pharmaceuticals, a clinical-stage TechBio company, has reported its first clinical proof of concept from REC-4881, an allosteric MEK 1/2 inhibitor targeting familial adenomatous polyposis, showing significant reductions in precancerous polyps. The company is now working with the U.S. Food and Drug Administration to determine next steps, with updates expected in the second half of 2026. Recursion’s pipeline includes five wholly owned programs, with key milestones anticipated over the next 12 to 18 months, including REC-1245, an RBM39 degrader in Phase 1 for solid tumors and lymphomas that was discovered and advanced to human testing in about 18 months using its AI platform. The company ended the first quarter with $665 million in cash equivalents, reduced cash operating expenses by 30% year-over-year, and expects full-year cash operating expenses below $390 million, with partnerships with Sanofi and Roche generating more than $500 million in inflows. Analysts rate the stock a Moderate Buy with an average target price of $6.64, implying 111.47% upside potential.